(Q35696255)

9 August 2017

1 reference

title

Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan/HCT). (English)

1 reference

9 August 2017

Steven G Chrysant

1

1 reference

9 August 2017

publication date

1 September 2003

1 reference

Expert Review of Cardiovascular Therapy

9 August 2017

published in

1 reference

9 August 2017

volume

1

1 reference

9 August 2017

issue

3

1 reference

9 August 2017

page(s)

335-343

1 reference

Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid?

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.3.335

Prevalence, treatment, and control of hypertension in the French population: data from a survey on high blood pressure in general practice, 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.3.335

Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.3.335

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.3.335

Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.3.335

A candesartan cilexetil/hydrochlorothiazide combination tablet provides effective blood pressure control in hypertensive patients inadequately controlled on monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.3.335

Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.3.335

Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.3.335

Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.3.335

Valsartan. A review of its pharmacology and therapeutic use in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.3.335

Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.3.335

Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.3.335

Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.3.335

Antihypertensive effects of valsartan/hydrochlorothiazide combination in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.3.335

A multicenter, randomized double-blind study of valsartan/hydrochlorothiazide combination versus amlodipine in patients with mild to moderate hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.3.335

Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.3.335

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.3.335

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.3.335

Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.3.335

Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.3.335

Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.3.335

21 January 2018

Identifiers

DOI

10.1586/14779072.1.3.335

1 reference

9 August 2017

1 reference